Prasad S. Adusumilli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Prasad S. Adusumilli has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
David R. Jones
Weill Cornell Medical College, New York, NY, USA; Thoracic Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
32 shared publicationsKyuichi Kadota
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Diagnostic Pathology, Kagawa University, Kagawa, Japan
32 shared publications- Takashi Eguchi
Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine , Matsumoto, Japan
26 shared publications William D. Travis
Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center New York New York USA
25 shared publicationsCamelia S. Sima
Department of Epidemiology and Biostatistics
21 shared publications- Valerie W. Rusch
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065
21 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (4)
Targeting the tumor, harboring the host: IL-7 receptor-targeted CARs to treat T-ALL
- 25 September 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (4)
Open AccessTargeting the tumor, harboring the host: IL-7 receptor-targeted CARs to treat T-ALL
- Open Access
- 15 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
IL7-Receptor–Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia
On the basis that T-cell acute lymphoblastic leukemia (T-ALL) cells overexpress IL7 receptor (IL7R), which promotes resistance to chemotherapy and disease relapse, here we develop IL7Rα (CD127)-targeted chimeric antigen receptor (CAR) T cells with low- and high-affinity single-chain variable fragments. We establish the antitumor efficacy of CD127 CAR against T-ALL cells in vitro, in female mouse models of T-ALL, and against blasts from patients with T-ALL using the patients' own T cells transduced with CD127 CAR. Antitumor efficacy is higher with low-affinity CAR T cells than high-affinity CAR T cells, albeit with fratricide of CAR T cells following eradication of CD127-overexpressing blasts. CRISPR-Cas9 knockout of CD127 eliminates fratricide at the risk of prolonged lymphopenia in vivo. To overcome fratricide, we investigate short-term ( < 7 days) co-culture with or without dasatinib, a tyrosine kinase inhibitor, versus a natural selection method (10 days) and demonstrate that co-culturing with dasatinib facilitates higher CAR T-cell yield, improved fitness, and preserved functionality. In vivo, dasatinib can be used to temporarily and reversibly suppress CAR T-cell activity. With this supporting translational data, we are initiating a trial with low-affinity CD127 CAR T cells for adult and pediatric patients with relapsed or refractory T-ALL.
- 15 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessIL7-Receptor–Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia
On the basis that T-cell acute lymphoblastic leukemia (T-ALL) cells overexpress IL7 receptor (IL7R), which promotes resistance to chemotherapy and disease relapse, here we develop IL7Rα (CD127)-targeted chimeric antigen receptor (CAR) T cells with low- and high-affinity single-chain variable fragments. We establish the antitumor efficacy of CD127 CAR against T-ALL cells in vitro, in female mouse models of T-ALL, and against blasts from patients with T-ALL using the patients' own T cells transduced with CD127 CAR. Antitumor efficacy is higher with low-affinity CAR T cells than high-affinity CAR T cells, albeit with fratricide of CAR T cells following eradication of CD127-overexpressing blasts. CRISPR-Cas9 knockout of CD127 eliminates fratricide at the risk of prolonged lymphopenia in vivo. To overcome fratricide, we investigate short-term ( < 7 days) co-culture with or without dasatinib, a tyrosine kinase inhibitor, versus a natural selection method (10 days) and demonstrate that co-culturing with dasatinib facilitates higher CAR T-cell yield, improved fitness, and preserved functionality. In vivo, dasatinib can be used to temporarily and reversibly suppress CAR T-cell activity. With this supporting translational data, we are initiating a trial with low-affinity CD127 CAR T cells for adult and pediatric patients with relapsed or refractory T-ALL.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 2. Estimation of cell death within 3-dimensional hydrogel tissue mimic following treatment with IRE and sIRE.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 2. Estimation of cell death within 3-dimensional hydrogel tissue mimic following treatment with IRE and sIRE.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Table 3. Pulse parameters used for conventional IRE and sIRE.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Table 3. Pulse parameters used for conventional IRE and sIRE.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 3. Fluorescent imaging of IRE and sIRE treatment effects on (A) MSTO-GM, (B) untransduced, and (C) CAR T cells embedded in 3D collagen mimics that were treated with various parameters of sIRE or IRE 24 hours post-treatment in vitro. 4x magnification images were scanned and stitched to illustrate PEF treatment area of effect within the whole well of a 24-well using a 2-pin probe electrodes with 4 mm spacing. Dead cells were identified by propidium iodide (red) and live cells identified with Calcein AM (green). (D–F) Area of cell death were quantified using script on FIJI ImageJ. Scale bar = 4 mm.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 3. Fluorescent imaging of IRE and sIRE treatment effects on (A) MSTO-GM, (B) untransduced, and (C) CAR T cells embedded in 3D collagen mimics that were treated with various parameters of sIRE or IRE 24 hours post-treatment in vitro. 4x magnification images were scanned and stitched to illustrate PEF treatment area of effect within the whole well of a 24-well using a 2-pin probe electrodes with 4 mm spacing. Dead cells were identified by propidium iodide (red) and live cells identified with Calcein AM (green). (D–F) Area of cell death were quantified using script on FIJI ImageJ. Scale bar = 4 mm.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 4. Intratumoral T cell viability after sIRE or IRE in an immunocompetent syngeneic flank tumor model.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 4. Intratumoral T cell viability after sIRE or IRE in an immunocompetent syngeneic flank tumor model.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 7. sIRE promotes infiltration of CAR T cells with minimal killing of preexisting intratumoral T cells.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 7. sIRE promotes infiltration of CAR T cells with minimal killing of preexisting intratumoral T cells.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 5. Transwell migration assay of CAR T cells when exposed to sIRE and IRE conditioned media in vitro.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 5. Transwell migration assay of CAR T cells when exposed to sIRE and IRE conditioned media in vitro.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 1. Mesothelioma and T cell viability at 24 hours post-IRE in vitro. Mesothelioma cell lines.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Figure 1. Mesothelioma and T cell viability at 24 hours post-IRE in vitro. Mesothelioma cell lines.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Table 2. Cell viability material properties.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Irreversible Electroporation Enhances Solid Tumor Infiltration and Selective Cancer Cell Lysis by CAR T Cells
Supplemental Table 2. Cell viability material properties.